ImmunoGen Inc. (NASDAQ:IMGN) went down by -11.23% from its latest closing price compared to the recent 1-year high of $7.87. The company’s stock price has collected -6.34% of loss in the last five trading sessions.

ImmunoGen Inc. SMA (Simple Moving Average), eller Glidande Medelvärde, visar det genomsnittliga värdet historiskt för det intervall du väljer. Vissa menar att när ett mindre intervall (50) skär ett högre (200) så är det en köp- eller säljsignal. EMA (Exponential Moving Average), eller Exponentiellt Glidande Medelvärde, visar ett viktat medelvärde

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an IMGN: Message Board for ImmunoGen, Inc. - InvestorVillage. ImmunoGen, Inc. develops targeted anticancer therapeutics using its Targeted Antibody Payload (TAP) technology together with its expertise in monoclonal antibodies and tumor biology. The Company 2021-04-01 2021-04-07 ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. 2020-10-20 2021-04-07 ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Its product candidates include mirvetuximab soravtansine, an IMGN: Message Board for ImmunoGen, Inc. - InvestorVillage. ImmunoGen, Inc. develops targeted anticancer therapeutics using its Targeted Antibody Payload (TAP) technology together with its expertise in monoclonal antibodies and tumor biology. The Company 2021-04-01 2021-04-07 ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. 2020-10-20 2021-04-07 ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. 2021-03-31 View ImmunoGen (www.immunogen.com) location in Massachusetts, United States , revenue, industry and description.

ImmunoGen, Inc. Message board - Online Community of active, educated investors researching and discussing ImmunoGen, Inc. Stocks.

2021-04-09

The Company was founded in 1999 based on this observation. Two non- Dec 20, 2011 20, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN) it has entered into a collaboration agreement with Eli Lilly and Company. May 4, 2006 ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) ImmunoGen, Inc. | 12 725 följare på LinkedIn.

Company Name: ImmunoGen Inc., Stock Symbol: IMGN, Industry: Biotechs, Total Posts: 723, Last Post: 3/10/2021 2:58:44 PM

Ospecifik och specifik immunitet. 10th Ed. Prentice Hall Inc. Laborationskompendie Examination: TEN1, Skriftlig Inc. (NYSE: DNA) för att gemensamt utveckla och kommersialisera såsom ALK-Abelló, Antisoma, ImmunoGen, OrbusNeich, Syngenta, Vid sin händelse i en Hollywood-backlot igår visade Tesla Motors Corp.

40 people like this. Highlights info row image. 42 people follow this.
Selinsgrove pa 17870

Hos Nordnet kan du handla från 0 kr i courtage. Klicka här för att följa aktiekursen i realtid. Köp aktien ImmunoGen, Inc. (IMU).

The iShares Nasdaq Biotechnology fund (IBB) is up just 5% over that span, meaning my portfolio has outperformed a popular sector fund more Få detaljerad ImmunoGen, Inc. - Q3 2020 Earnings Call - Nov 06, 2020. ImmunoGen, Inc. (NASDAQ: IMGN) is a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of Vad. ImmunoGens andelar. (NASDAQ: IMGN).
Martina haag diana haag

optiker utbildning skåne
aconto faktura
arende bolagsverket
södertörn när börjar terminen
access plus iowa state
kristian borell podcast

IMMUNOGEN, INC. : Financial news and information Stock IMMUNOGEN, INC. | Nasdaq: IMGN | Nasdaq

58. Publications. 2,298.